Sugi Predict

Sugi Predict / Targets / CDC25B

CDC25B

M-phase inducer phosphatase 2 · P30305 · CDC25B on Sugi Atlas →

85,544 patent compounds predicted against CDC25B, 51,071 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL150458 SCHEMBL150458 0.56 11/20
SCHEMBL155510 SCHEMBL155510 0.45 10/20
SCHEMBL155511 SCHEMBL155511 0.45 10/20
SCHEMBL175459 SCHEMBL175459 0.46 9/20
SCHEMBL82554 SCHEMBL82554 0.69 7/20
SCHEMBL112795 SCHEMBL112795 0.56 6/20
Naphthoquinone Naphthoquinone (SCHEMBL106247) 0.54 6/20
SCHEMBL163864 SCHEMBL163864 0.51 6/20
SCHEMBL181078 SCHEMBL181078 0.46 6/20
SCHEMBL170030 SCHEMBL170030 0.42 6/20
SCHEMBL154918 SCHEMBL154918 0.40 6/20
SCHEMBL45540 SCHEMBL45540 0.34 6/20
Naphthoquinone Naphthoquinone (SCHEMBL42139) 1.00 5/20
Naphthoquinone Naphthoquinone (SCHEMBL60195) 0.67 5/20
SCHEMBL125298 SCHEMBL125298 0.56 5/20
SCHEMBL134428 SCHEMBL134428 0.53 5/20
Ubiquinone Qo Ubiquinone Qo (SCHEMBL49420) 0.45 5/20
Floctafenine Floctafenine (SCHEMBL26841) 0.44 5/20
SCHEMBL181077 SCHEMBL181077 0.42 5/20
SCHEMBL181126 SCHEMBL181126 0.42 5/20

Clinical trials — most relevant to CDC25B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer PHASE2/PHASE3NOT_YET_RECRUITING
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression PHASE3RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia PHASE1WITHDRAWN
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC25B binder may also engage these)

ProteinNameSimilarity
P30306 — 1.000 P30306 →
P48966 — 1.000 P48966 →
CDC25A M-phase inducer phosphatase 1 0.998 landscape →
A7MBD1 — 0.996 A7MBD1 →
P48965 — 0.994 P48965 →
P48964 — 0.994 P48964 →
Q29029 — 0.992 Q29029 →
P30308 — 0.990 P30308 →
P30311 — 0.990 P30311 →
CDC25C M-phase inducer phosphatase 3 0.989 landscape →
P30310 — 0.988 P30310 →
P30309 — 0.985 P30309 →
A0JPN4 — 0.982 A0JPN4 →
A5D7P0 — 0.982 A5D7P0 →
A4QNA8 — 0.980 A4QNA8 →
Q9H8N7 — 0.980 Q9H8N7 →
Q5D1E8 — 0.980 Q5D1E8 →
P0C0N9 — 0.980 P0C0N9 →
Q9BY84 — 0.979 Q9BY84 →
Q64210 — 0.979 Q64210 →
P0C0N8 — 0.979 P0C0N8 →
Q9BRS8 — 0.979 Q9BRS8 →
Q6P9P8 — 0.979 Q6P9P8 →
Q80Y19 — 0.979 Q80Y19 →
Q5RHD1 — 0.979 Q5RHD1 →
F1QN48 — 0.978 F1QN48 →
Q14153 — 0.978 Q14153 →
F7EA39 — 0.978 F7EA39 →
Q3UZ45 — 0.978 Q3UZ45 →
Q7TT79 — 0.978 Q7TT79 →